On August 6, Cinda Biopharmaceutical Group announced that its world's first PD-1/IL-2α-Biased bispecific antibody fusion protein IBi363 combined with bevacizumab compared with investigators' choice of treatment to treat advanced colorectal cancer where previous standard treatments failed or were intolerant, and completed the administration of the first patient.

Zhitongcaijing · 4d ago
On August 6, Cinda Biopharmaceutical Group announced that its world's first PD-1/IL-2α-Biased bispecific antibody fusion protein IBi363 combined with bevacizumab compared with investigators' choice of treatment to treat advanced colorectal cancer where previous standard treatments failed or were intolerant, and completed the administration of the first patient.